DA42 - Gastritis: Complete ICD-11 Coding Guide

1. Introduction

Gastritis represents one of the most commonly diagnosed gastrointestinal conditions in worldwide clinical practice. Fundamentally characterized as a lesion of the gastric mucosa that involves epithelial damage, mucosal inflammation and regeneration of epithelial cells, this condition affects millions of people globally and constitutes a significant diagnostic and therapeutic challenge for healthcare professionals.

The clinical importance of gastritis transcends its high prevalence. This condition can present in acute or chronic form, with manifestations ranging from mild discomfort to serious complications that significantly compromise patients' quality of life. Gastritis can be caused by multiple etiological factors, including infectious agents (notably Helicobacter pylori), medications (especially nonsteroidal anti-inflammatory drugs), chemical agents, autoimmune reactions and other pathological mechanisms.

From a public health perspective, gastritis represents considerable impact on healthcare systems worldwide. The condition generates substantial demand for medical consultations, endoscopic examinations, pharmacological treatments and, in complicated cases, hospital admissions. Furthermore, when not adequately diagnosed and treated, chronic gastritis can progress to more serious conditions, including peptic ulcers and, in specific situations, increase the risk of gastric malignancies.

The correct coding of gastritis using the DA42 code from ICD-11 is critical for several reasons. First, it enables accurate epidemiological recording of the condition, facilitating prevalence and incidence studies. Second, it ensures appropriate reimbursement for services provided in public and private healthcare systems. Third, it enables tracking of clinical outcomes and evaluation of the effectiveness of therapeutic interventions. Finally, appropriate coding contributes to effective communication between healthcare professionals and institutions, ensuring continuity and quality in patient care.

2. Correct ICD-11 Code

Code: DA42

Description: Gastritis

Parent category: Diseases of the stomach

Official definition: Gastritis is defined by ICD-11 as a lesion of the gastric mucosa that involves epithelial damage, mucosal inflammation, and regeneration of epithelial cells, excluding any dysplastic or neoplastic epithelial abnormality. The condition is caused by multiple etiological factors, including infectious agents (such as bacteria, viruses, and parasites), drugs (particularly nonsteroidal anti-inflammatory drugs and other gastrolesive medications), chemical agents (including alcohol and corrosive substances), autoimmune reactions, and other pathophysiological mechanisms.

The diagnosis of gastritis is established through objective methods, specifically by histopathology (microscopic analysis of gastric mucosal biopsies) and/or upper gastrointestinal endoscopy (direct visualization of mucosal changes). The classification of gastritis is based on clinical course, being categorized as acute (sudden onset, rapid progression) or chronic (gradual development, prolonged persistence).

It is fundamental to understand that code DA42 encompasses gastritis as a pathological entity confirmed by objective diagnostic methods, not applying to isolated dyspeptic symptoms or gastric discomfort without adequate diagnostic confirmation. Appropriate coding requires clear documentation of gastric inflammation through endoscopic and/or histopathological evidence.

3. When to Use This Code

The code DA42 should be used in specific clinical scenarios where there is objective confirmation of gastric mucosal inflammation. Below, we present detailed practical situations that justify the use of this code:

Scenario 1: Acute Gastritis Confirmed by Endoscopy A patient presents with severe epigastric pain of sudden onset, nausea and vomiting for 48 hours, with a history of recent use of nonsteroidal anti-inflammatory drugs for musculoskeletal pain treatment. Upper gastrointestinal endoscopy demonstrates diffuse erythema of the gastric mucosa, edema and multiple superficial erosions in the antrum and gastric body. Biopsies reveal acute inflammatory infiltrate with neutrophils in the lamina propria. This scenario fully justifies the code DA42, with possible specification of acute erosive gastritis.

Scenario 2: Chronic Gastritis Associated with Helicobacter pylori A patient with recurrent complaints of epigastric discomfort, postprandial fullness and occasional heartburn for several months. Endoscopy demonstrates gastric mucosa with nodular pattern in the antrum, moderate erythema and mottled pattern. Histopathological analysis of biopsies confirms active chronic gastritis with presence of Helicobacter pylori identified by special staining or urease test. The code DA42 is appropriate, and may be complemented with an additional code to specify the infectious agent.

Scenario 3: Autoimmune Gastritis A patient with megaloblastic anemia investigated through upper gastrointestinal endoscopy. The examination reveals gastric mucosa of the body and fundus with atrophic appearance, mucosal pallor and prominent submucosal vessels. Biopsies demonstrate chronic gastritis with glandular atrophy, intestinal metaplasia and lymphocytic inflammatory infiltrate. Positive serology for anti-parietal cell and anti-intrinsic factor antibodies confirms autoimmune nature. The code DA42 is appropriate for this specific form of gastritis.

Scenario 4: Chemical Gastritis Induced by Biliary Reflux A patient previously submitted to gastric surgery presents with persistent dyspeptic symptoms. Endoscopy reveals gastric mucosa with diffuse erythema, edema and presence of bile in the stomach. Histopathology demonstrates gastritis with characteristics of chemical injury, including foveolar hyperplasia, lamina propria edema and capillary vasodilation, with minimal inflammation. This pattern justifies the use of code DA42 for chemical gastritis.

Scenario 5: Acute Gastritis from Ingestion of Corrosive Substance A patient admitted to the emergency department following accidental or intentional ingestion of corrosive substance (acid or alkali). Endoscopy performed within the first 24 hours demonstrates gastric mucosal lesions with intense erythema, edema, erosions and areas of superficial necrosis. The code DA42 is appropriate for documenting severe acute gastritis resulting from chemical exposure.

Scenario 6: Eosinophilic Gastritis Confirmed Histologically A patient with upper gastrointestinal symptoms, including abdominal pain, nausea and vomiting, with possible history of atopy. Endoscopy may show gastric mucosa with erythema, edema or nodular appearance. Biopsies reveal dense eosinophilic infiltrate in the gastric mucosa, exceeding normal limits. The code DA42 is appropriate for this specific form of gastritis, and may be complemented with additional specifiers when available.

4. When NOT to Use This Code

It is fundamental to recognize situations where the DA42 code is not appropriate, avoiding coding errors that compromise epidemiological records and administrative processes:

Functional Dyspepsia Without Evidence of Gastritis: Patients with chronic dyspeptic symptoms (epigastric pain or discomfort, fullness, early satiety) who undergo upper endoscopy with normal results or nonspecific minimal alterations, without histopathological evidence of inflammation, should not receive the DA42 code. These cases correspond to functional disorders that require specific codes from the category of gastroduodenal motor or secretory disorders.

Peptic Ulcer: When endoscopy identifies a defined gastric or duodenal ulcer (loss of substance extending beyond the muscular layer of the mucosa), even if accompanied by adjacent gastritis, the primary code should be the specific one for peptic ulcer, not DA42. Associated gastritis may be coded secondarily if clinically relevant.

Gastric Neoplasms: Dysplastic lesions, adenomas, or gastric carcinomas require specific oncological codes. Even when there is underlying chronic gastritis (common in cases of gastric cancer associated with atrophic gastritis), the primary code should reflect the neoplasm, not the gastritis.

Structural Anatomical Alterations: Conditions such as gastric stenosis, gastric diverticula, or other acquired anatomical alterations of the stomach are coded with DA40, not DA42, even if they present secondary inflammation.

Gastric Vascular Disorders: Lesions such as angiodysplasias, gastric varices, or portal hypertensive gastropathy, although they may cause mucosal alterations, are appropriately coded with DA43, not DA42.

Isolated Symptoms Without Diagnostic Confirmation: Patients with complaints of epigastric pain, nausea, or other upper gastrointestinal symptoms who have not undergone endoscopic investigation or whose examinations did not confirm gastritis should not receive the DA42 code. Coding should reflect the symptoms presented until adequate investigation is performed.

5. Step-by-Step Coding Process

Step 1: Assess Diagnostic Criteria

The first fundamental step in appropriate gastritis coding is to confirm that the diagnosis has been established through adequate objective methods. Gastritis should not be diagnosed based solely on clinical symptoms, as dyspeptic manifestations may result from multiple conditions.

Confirmation by Upper Gastrointestinal Endoscopy: Direct visualization of the gastric mucosa through endoscopy allows identification of characteristic gastritis alterations, including erythema (mucosal redness), edema (mucosal thickening and glossy appearance), erosions (superficial epithelial losses), nodular pattern, mucosal friability, and presence of exudate. Endoscopic photographic documentation strengthens diagnostic evidence.

Histopathological Confirmation: Microscopic analysis of gastric biopsies represents the gold standard for definitive diagnosis of gastritis. Histopathological examination identifies inflammatory infiltrate (neutrophils in acute gastritis, lymphocytes and plasma cells in chronic gastritis), epithelial damage, glandular atrophy, intestinal metaplasia, and presence of infectious agents such as Helicobacter pylori. Ideally, multiple biopsies should be obtained from different gastric regions (antrum, body, angular incisure) following established protocols.

Complementary Tests: Depending on etiological suspicion, additional tests may be necessary, including rapid urease test, serology for Helicobacter pylori, screening for anti-parietal cell and anti-intrinsic factor antibodies (autoimmune gastritis), and serum gastrin measurement.

Step 2: Verify Specifiers

After confirming the diagnosis of gastritis, it is essential to characterize specific aspects that may influence coding and clinical management:

Duration and Clinical Course: Differentiate acute gastritis (sudden onset, intense symptoms, rapid progression) from chronic gastritis (gradual development, persistent or recurrent symptoms, characteristic histological changes of chronicity). This distinction has important therapeutic and prognostic implications.

Etiology: Identify when possible the causal factor: infectious (Helicobacter pylori, viruses, parasites), medication-related (nonsteroidal anti-inflammatory drugs, other drugs), chemical (alcohol, bile, corrosive substances), autoimmune, or other specific causes. Etiology may justify additional complementary codes.

Morphological Pattern: Characterize whether gastritis is erosive or non-erosive, focal or diffuse, and whether there are special characteristics such as atrophy, intestinal metaplasia, or specific cellular infiltrate (eosinophilic, lymphocytic, granulomatous).

Severity: Document the extent and severity of inflammatory alterations, using standardized classification systems when available, such as the updated Sydney system for chronic gastritis.

Step 3: Differentiate from Other Codes

DA40 - Acquired anatomical alterations of the stomach: This code is used for structural conditions of the stomach, such as stenoses, acquired diverticula, fistulas, or anatomical deformities resulting from pathological or surgical processes. The key difference is that DA40 refers to alterations in stomach architecture or shape, while DA42 refers specifically to mucosal inflammation. A patient may have both conditions, but the primary coding should reflect the clinically most relevant problem in the context of the clinical encounter.

DA41 - Gastroduodenal motor or secretory disorders: This code encompasses functional conditions such as functional dyspepsia, gastroparesis, and acid secretion disturbances without evidence of mucosal inflammation. The key difference is that DA41 is used when there are upper gastrointestinal symptoms but endoscopic and histopathological investigation does not demonstrate gastritis. Patients with dyspeptic symptoms and normal endoscopy receive DA41, not DA42.

DA43 - Vascular disorders of the stomach: This code is appropriate for conditions such as portal hypertensive gastropathy, gastric angiodysplasias, gastric varices, and other vascular lesions. The key difference is that DA43 focuses on primary vascular alterations, while DA42 refers to mucosal inflammation. Although portal hypertensive gastropathy may present with mucosal alterations, its pathophysiology is vascular, not inflammatory, justifying code DA43.

Step 4: Necessary Documentation

For appropriate and complete gastritis coding, medical documentation must include:

Mandatory Information Checklist:

Detailed description of endoscopic findings with specific lesion location (antrum, body, fundus, cardia)
Histopathological examination result with characterization of inflammation type and intensity
Identification of etiological agent when applicable (Helicobacter pylori, others)
Classification regarding clinical course (acute or chronic)
Presence or absence of erosions, atrophy, metaplasia
Clinical symptoms presented by the patient
Identified risk factors (medication use, alcohol, family history)
Relevant comorbidities

Adequate Documentation: Documentation must be clear, objective, and complete, allowing other professionals to understand the diagnosis and coding justification. Use standardized medical terminology and, when possible, internationally recognized classification systems.

6. Complete Practical Example

Clinical Case

A 52-year-old female patient presents to gastroenterology consultation with a complaint of recurrent epigastric pain for approximately four months. The pain is described as burning, moderate intensity, worsening after meals and occasionally waking the patient during the night. Additionally, she reports occasional nausea, sensation of fullness after eating, and unintentional weight loss of approximately three kilograms during this period.

In the clinical history, the patient reports frequent use of nonsteroidal anti-inflammatory drugs over the past two years for treatment of knee osteoarthritis. She denies tobacco use but admits moderate alcohol consumption (two to three drinks per week). She has no relevant family history of gastrointestinal diseases or neoplasms.

On physical examination, she appears in good general condition, with normal color and hydration. Abdomen is flat with present bowel sounds, mild pain on palpation in the epigastrium, without palpable masses or signs of peritoneal irritation. Remainder of physical examination without significant findings.

Given the clinical presentation suggestive of gastroduodenal disease, upper gastrointestinal endoscopy was requested. The endoscopic examination revealed normal esophageal mucosa, with no alterations in the cardia and gastric fundus. In the gastric body and antrum, mucosa showed moderate diffuse erythema, edema, mottled pattern, and multiple superficial erosions distributed irregularly, measuring between 3 and 8 millimeters. Pylorus and duodenal bulb without alterations. Biopsies were performed from the antrum (two samples) and gastric body (two samples) for histopathological analysis.

Histopathological examination demonstrated gastric mucosa with preserved architecture, presence of mixed inflammatory infiltrate in the lamina propria, composed predominantly of lymphocytes and plasma cells, with focal neutrophils. Epithelial damage was observed with degeneration of superficial cells and active epithelial regeneration. Giemsa special staining identified the presence of curved bacilli compatible with Helicobacter pylori in moderate density. No glandular atrophy, intestinal metaplasia, or dysplasia were observed.

Step-by-Step Coding

Criteria Analysis:

Diagnostic Confirmation: The diagnosis of gastritis was established through appropriate objective methods - upper gastrointestinal endoscopy with direct visualization of characteristic mucosal alterations (erythema, edema, erosions) and histopathological confirmation demonstrating inflammation of the gastric mucosa.
Characterization of Gastritis: This is active chronic gastritis (presence of lymphocytes and plasma cells indicates chronicity; neutrophils indicate activity), erosive (presence of endoscopic erosions), associated with Helicobacter pylori.
Multifactorial Etiology: Multiple contributing factors identified: Helicobacter pylori infection (confirmed histologically), chronic use of nonsteroidal anti-inflammatory drugs, and alcohol consumption.
Exclusion of Other Conditions: There is no evidence of peptic ulcer disease (the erosions are superficial, not penetrating the muscularis mucosae), neoplasm (absence of dysplasia or malignancy), structural anatomical alterations, or vascular disorders.

Code Selected: DA42 - Gastritis

Complete Justification:

The code DA42 is most appropriate for this case because:

There is objective confirmation of inflammation of the gastric mucosa by endoscopy and histopathology
The findings correspond precisely to the ICD-11 definition of gastritis (gastric mucosal lesion with epithelial damage, inflammation, and cellular regeneration)
The identified etiology (Helicobacter pylori, anti-inflammatory drugs) is contemplated in the code definition
There are no excluding conditions requiring other primary codes

Applicable Complementary Codes:

Depending on the coding system and institutional needs, the following may be added:

Code to specify presence of Helicobacter pylori (when specific category for infectious agent is available)
External code to document drug-induced gastritis (if system uses external cause codes)
Codes for relevant associated symptoms for complete documentation of the clinical presentation

Final Documentation: The medical record should include all diagnostic elements mentioned, allowing appropriate audit and fully justifying the coding selected.

7. Related Codes and Differentiation

Within the Same Category

DA40: Acquired anatomical alterations of the stomach

When to use DA40 vs. DA42: The code DA40 is appropriate when the primary condition involves structural or anatomical alteration of the stomach, such as gastric stenosis (narrowing of the lumen), acquired diverticulum (saccular protrusion of the wall), gastroenteric fistula, or deformities resulting from previous scarring or surgical processes. The main difference is that DA40 refers to the form and structure of the organ, while DA42 refers to inflammation of the mucosa.

Main difference: DA40 codes permanent macroscopic morphological alterations of gastric architecture; DA42 codes inflammatory process of the mucosa that may be reversible with appropriate treatment. A patient may have both conditions simultaneously (for example, pyloric stenosis secondary to chronic scarring gastritis), a situation in which both codes may be used with appropriate designation of principal and secondary codes.

DA41: Gastroduodenal motor or secretory disorders

When to use DA41 vs. DA42: The code DA41 is used for functional disorders of the stomach and duodenum, including functional dyspepsia (chronic dyspeptic symptoms without identifiable organic cause), gastroparesis (delayed gastric emptying), acid secretion disorders, and other motor disorders. This code is appropriate when the patient presents with upper gastrointestinal symptoms but endoscopic and histopathological investigation does not demonstrate gastritis or other organic lesion.

Main difference: DA41 represents functional disorders without demonstrable inflammatory substrate or mucosal lesion; DA42 requires objective evidence of gastric inflammation. The distinction is fundamental: patients with dyspeptic symptoms and normal endoscopy receive DA41; those with endoscopic and/or histopathological evidence of gastritis receive DA42.

DA43: Vascular disorders of the stomach

When to use DA43 vs. DA42: The code DA43 is appropriate for gastric vascular conditions, including portal hypertensive gastropathy (mucosal alterations secondary to portal hypertension), angiodysplasias (vascular malformations), gastric antral vascular ectasia, gastric varices, and other vascular lesions. These conditions have primarily vascular, not inflammatory, pathophysiology.

Main difference: DA43 codes vascular pathology of the stomach; DA42 codes mucosal inflammation. Although portal hypertensive gastropathy may cause endoscopically visible mucosal alterations, the mechanism is vascular congestion, not inflammation, justifying DA43. The histopathological distinction is clear: vascular gastropathy shows capillary and venular dilation with minimal inflammation; gastritis shows significant inflammatory infiltrate.

Differential Diagnoses

Peptic Ulcer: Differs from gastritis by the depth of the lesion. Erosions in gastritis are superficial, limited to the mucosa; ulcers penetrate beyond the muscularis mucosae. Endoscopically, ulcers present a defined crater with raised borders; erosive gastritis shows multiple superficial losses without deep crater.

Gastroesophageal Reflux Disease: Although it may cause similar symptoms, reflux primarily affects the esophagus. Patients with reflux may have concomitant gastritis, but these are distinct conditions that require separate codes.

Early Gastric Neoplasms: Dysplastic lesions or early carcinomas may mimic gastritis endoscopically. The distinction is histopathological, emphasizing the importance of adequate biopsies in suspicious lesions.

Functional Dyspepsia: Differs by the absence of organic alterations. Symptoms similar to gastritis, but endoscopy and histology normal or with minimal nonspecific alterations.

8. Differences with ICD-10

In the International Classification of Diseases, 10th Revision (ICD-10), gastritis was coded primarily with codes K29 (Gastritis and duodenitis), with subdivisions including:

K29.0 - Acute hemorrhagic gastritis
K29.1 - Other acute gastritis
K29.2 - Alcoholic gastritis
K29.3 - Chronic superficial gastritis
K29.4 - Chronic atrophic gastritis
K29.5 - Chronic gastritis, unspecified
K29.6 - Other gastritis
K29.7 - Gastritis, unspecified

Main Changes in ICD-11:

The transition to ICD-11 with code DA42 represents simplification and modernization of gastritis coding. The main changes include:

Simplified Structure: While ICD-10 presented multiple subdivisions of gastritis based on specific characteristics (hemorrhagic, atrophic, alcoholic), ICD-11 adopts a more unified approach with code DA42, allowing additional specifiers when necessary, but avoiding excessive fragmentation.

Emphasis on Diagnostic Methods: The ICD-11 definition explicitly states that gastritis should be diagnosed by histopathology and/or endoscopy, emphasizing the need for objective confirmation, unlike ICD-10 which was less specific regarding diagnostic criteria.

Integration with Etiology: ICD-11 explicitly recognizes in its definition the multiple etiologies of gastritis (infectious, medication-induced, chemical, autoimmune), facilitating comprehensive understanding of the condition.

Practical Impact:

For healthcare professionals, the change requires familiarity with the new code DA42 and understanding that detailed subdivisions from ICD-10 are now incorporated through additional specifiers when available in the coding system used. For purposes of historical epidemiological comparison, it is necessary to appropriately map ICD-10 codes K29.x to ICD-11 DA42, recognizing that granularity may differ between classifications. Health information systems should implement appropriate correspondence tables to ensure continuity in epidemiological records during the transition between classifications.

9. Frequently Asked Questions

1. How is a definitive diagnosis of gastritis made?

The definitive diagnosis of gastritis requires objective confirmation through complementary methods. Upper gastrointestinal endoscopy is the fundamental examination, allowing direct visualization of the gastric mucosa and identification of characteristic alterations such as erythema, edema, erosions, friability, and specific patterns of injury. During the endoscopic procedure, biopsies should be performed from multiple gastric regions (antrum, body, angular incisure) for histopathological analysis. Histopathological examination represents the diagnostic gold standard, identifying inflammatory infiltrate, predominant cell type, presence of infectious agents, degree of inflammatory activity, atrophy, metaplasia, and other microscopic alterations. Complementary tests such as Helicobacter pylori investigation (rapid urease test, histology, serology, breath test) and serum measurements (gastrin, pepsinogen, specific antibodies) may be necessary depending on the suspected etiology. Diagnosis should not be established solely based on clinical symptoms, as dyspeptic manifestations are nonspecific and may result from multiple conditions.

2. Is gastritis treatment available in public health systems?

Gastritis treatment is generally available in public health systems in various countries, although accessibility and coverage may vary according to local resources and organization of health services. Fundamental medications for gastritis treatment include proton pump inhibitors (omeprazole, pantoprazole, lansoprazole), H2 receptor antagonists (ranitidine, famotidine), antacids, and when indicated for Helicobacter pylori eradication, antibiotics (clarithromycin, amoxicillin, metronidazole) combined with proton pump inhibitors. These medications are included in essential medication lists of international health organizations and are generally included in public system formularies. Upper gastrointestinal endoscopy, essential for diagnosis, is also usually available in public services, although there may be waiting lists depending on demand and installed capacity. Access to a gastroenterologist specialist may vary, with some systems offering care primarily at the primary care level with referral to a specialist in selected cases.

3. How long does gastritis treatment last?

The duration of gastritis treatment varies significantly depending on the etiology, severity, and type of gastritis. For mild acute gastritis, symptomatic treatment with proton pump inhibitors or H2 antagonists may be necessary for two to four weeks, with complete resolution often observed in this period. Chronic gastritis requires a more prolonged approach, especially when associated with Helicobacter pylori. Treatment for eradication of this bacterium typically involves triple or quadruple therapy for 10 to 14 days, followed by additional acid suppression for four to eight weeks. Eradication testing should be performed at least four weeks after completion of antibiotic treatment. Autoimmune gastritis requires chronic management, including lifelong vitamin B12 replacement when there is deficiency. Anti-inflammatory-induced gastritis improves with discontinuation of the offending medication when possible, associated with acid suppression; if use of anti-inflammatory is indispensable, continuous gastroprotection may be necessary. Endoscopic follow-up is indicated in selected cases, particularly when there is atrophy, intestinal metaplasia, or other risk factors for progression.

4. Can this code be used in medical certificates?

The code DA42 can be used in medical certificates when appropriate, but specific considerations must be observed. Medical certificates have the purpose of documenting a health condition that justifies absence from work, school, or other activities, and must contain sufficient information while respecting patient privacy. The use of ICD codes in certificates varies according to local legislation and regulations; some contexts require specification of the code, others allow only textual description of the condition. When the code is included, DA42 is appropriate if gastritis was confirmed by adequate diagnostic methods and is the cause of the absence. The period of absence should be clinically justifiable, generally short for uncomplicated acute gastritis (a few days), and may be more prolonged in severe or complicated cases. It is essential that the certificate reflect genuine clinical evaluation and not be issued based solely on subjective complaints without appropriate investigation. Professionals must follow ethical and legal principles in issuing certificates, adequately documenting the justification in the medical record.

5. Can gastritis progress to gastric cancer?

Certain types of chronic gastritis can increase the risk of developing gastric cancer, although progression is not inevitable and occurs in a minority of cases. Chronic gastritis associated with Helicobacter pylori represents a recognized risk factor, especially when it progresses to atrophic gastritis and intestinal metaplasia. The proposed progression sequence (Correa cascade) includes: chronic non-atrophic gastritis → atrophic gastritis → intestinal metaplasia → dysplasia → adenocarcinoma. This process is slow, occurring over decades, and only a small proportion of patients with chronic gastritis develop cancer. Factors that increase risk include the extent and severity of atrophy, type of intestinal metaplasia, presence of dysplasia, family history of gastric cancer, smoking, and dietary factors. Autoimmune gastritis with extensive atrophy of the gastric body also increases the risk of neoplasms, including adenocarcinoma and neuroendocrine tumors. Helicobacter pylori eradication can reduce the risk of progression, especially when performed before the development of severe atrophy. Endoscopic surveillance is recommended for patients with atrophic gastritis, extensive intestinal metaplasia, or dysplasia, with intervals determined according to the degree of risk.

6. What are the most common symptoms of gastritis?

The symptoms of gastritis are variable and nonspecific, and may include epigastric pain or discomfort (upper central region of the abdomen), often described as burning or heaviness. Nausea is common, and may or may not be associated with vomiting. Postprandial fullness (sensation of a full stomach after meals) and early satiety (feeling satisfied with a small amount of food) are frequent manifestations. Some patients report abdominal distension, excessive eructations (belching), or changes in appetite. In erosive or hemorrhagic gastritis, hematemesis (vomiting blood) or melena (darkened stools from digested blood) may occur, although significant bleeding is more common in peptic ulcer disease. It is important to recognize that many patients with endoscopically confirmed gastritis are asymptomatic or present with mild symptoms, while others with intense symptoms may have normal endoscopy. This discordance between symptoms and objective findings emphasizes that the diagnosis of gastritis should not be based exclusively on clinical manifestations, requiring confirmation by complementary methods.

7. Is there a difference between gastritis and peptic ulcer disease?

Gastritis and peptic ulcer disease are distinct conditions, although related and frequently confused. Gastritis is characterized by inflammation of the gastric mucosa, with alterations limited to the superficial mucosal layer. Erosions may occur in gastritis, but are superficial, not penetrating beyond the muscularis mucosae. Peptic ulcer disease represents a deeper lesion, with tissue loss that penetrates beyond the muscularis mucosae, reaching the submucosa or deeper layers. Endoscopically, ulcers present a defined crater with elevated edges and a fibrin-covered base; erosive gastritis shows multiple superficial losses without a deep crater. Histologically, ulcers demonstrate destruction of all mucosal layers with necrosis and transmural inflammation; gastritis shows inflammation limited to the mucosa. Both conditions may have similar etiologies (Helicobacter pylori, anti-inflammatories), but peptic ulcer disease generally causes more intense symptoms and has a greater risk of serious complications such as significant bleeding, perforation, or obstruction. Treatment is similar (acid suppression, Helicobacter pylori eradication when present), but ulcers require more prolonged therapy and endoscopic follow-up to confirm healing.

8. How to prevent gastritis?

The prevention of gastritis involves multiple strategies directed at the main etiological factors. Avoiding indiscriminate use of nonsteroidal anti-inflammatory drugs is fundamental; when use of these medications is necessary, the lowest effective dose should be used for the shortest possible time, preferably with concomitant gastroprotection (proton pump inhibitors) in at-risk patients. Moderation in alcohol consumption reduces the risk of chemical gastritis. Avoiding smoking contributes to gastric health, as tobacco impairs mucosal defense mechanisms. Healthy eating habits, including regular meals, adequate chewing, and avoiding foods that cause individual discomfort, are beneficial. Stress management, although not a direct cause of gastritis, can reduce dyspeptic symptoms. Prevention of Helicobacter pylori infection involves hygiene measures, including proper hand washing, consumption of treated water, and foods prepared under appropriate hygienic conditions. In high-prevalence populations, strategies for screening and eradication of Helicobacter pylori may be considered. For individuals with a history of previous gastritis, regular medical follow-up and adherence to prescribed treatment are essential to prevent recurrences and complications. Patients on chronic use of gastric-damaging medications should discuss with their physician therapeutic alternatives or gastroprotection strategies.

Conclusion

Appropriate coding of gastritis using the DA42 code from ICD-11 requires a clear understanding of the condition's definition, objective diagnostic criteria, and differentiation from other gastric pathologies. This article provided comprehensive guidance for health professionals, emphasizing that gastritis should be diagnosed through objective methods (endoscopy and/or histopathology), not solely based on clinical symptoms. Appropriate documentation and accurate coding are essential for accurate epidemiological records, appropriate reimbursement of services, and effective communication between professionals and health institutions. The transition from ICD-10 to ICD-11 represents modernization of the classification, with a simplified structure while maintaining the specificity necessary for clinical practice. Professionals should familiarize themselves with the DA42 code and its applications, ensuring quality in the documentation and coding of this common and clinically relevant gastrointestinal condition.

External References

This article was developed based on reliable scientific sources:

References verified on 2026-02-04

Gastritis

Share